1. Home
  2. ZLAB vs PTGX Comparison

ZLAB vs PTGX Comparison

Compare ZLAB & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

HOLD

Current Price

$25.92

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$139.61

Market Cap

9.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZLAB
PTGX
Founded
2013
2006
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
9.3B
IPO Year
2017
2016

Fundamental Metrics

Financial Performance
Metric
ZLAB
PTGX
Price
$25.92
$139.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
13
Target Price
$49.60
★ $108.23
AVG Volume (30 Days)
★ 760.5K
562.1K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 38.46
N/A
EPS
N/A
★ 2.35
Revenue
★ $460,156,000.00
N/A
Revenue This Year
$9.75
$874.25
Revenue Next Year
$26.03
N/A
P/E Ratio
★ N/A
$60.61
Revenue Growth
★ 15.33
N/A
52 Week Low
$15.96
$62.24
52 Week High
$34.72
$160.81

Technical Indicators

Market Signals
Indicator
ZLAB
PTGX
Relative Strength Index (RSI) 55.31 41.98
Support Level $24.81 $130.63
Resistance Level $27.20 $142.20
Average True Range (ATR) 0.82 4.88
MACD -0.11 -0.71
Stochastic Oscillator 63.71 30.28

Price Performance

Historical Comparison
ZLAB
PTGX

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: